"We are truly appreciative for the invitation that allowed us to share our vision for improving metastatic melanoma care with physicians and researchers at MD Anderson," stated Mr. Joyce.
The slide-deck of Aethlon's presentation can be accessed on the company's website at: http://aethlonmedical. investorroom.com/ index.php?s=19.
Over the past 70 years, The University of Texas MD Anderson Cancer Center has become the world's premier center devoted exclusively to the prevention, treatment and eradication of cancer through research. For eight of the past 10 years, MD Anderson has ranked No. 1 in cancer care in the "Best Hospitals" survey published by U.S. News & World Report. In fiscal year 2011, more than 108,000 people — about one-third of them new patients — sought the high-quality care that has made MD Anderson so widely respected. There were nearly 10,000 registrants on clinical trials exploring novel treatments, the largest such program in the nation.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs
Broadwind Energy (BWEN) applies decades of deep industrial
expertise to innovate integrated solutions for customers in the energy
and infrastructure markets. From gears and gearing systems for wind, oil
and gas and mining applications to wind towers, to comprehensive
remanufacturing of gearboxes and blades, to operations and maintenance
services, and weldments, we have solutions for the 
A123 Systems, Inc. (AONE) is a leading developer and manufacturer of advanced lithium-ion batteries and energy 
Excellon Resources Inc. (
About TSX 
Torex Gold Resources Inc. (TSX: TXG) is last at $1.920, up 0.100 or 5.49% on 2,969,812 shares.
Petaquilla Minerals is an established gold mining company that
operates a producing gold mine in Panama. The 100 percent owned Molejon
gold mine reached commercial production in January 2010 and currently
operates at the rate of approximately 3,000 tonnes per day. 
About InvestorIdeas.com: